{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T18:26:49Z","timestamp":1776882409958,"version":"3.51.2"},"reference-count":177,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"FCT\/MCTES (PIDDAC)","doi-asserted-by":"publisher","award":["LA\/P\/0045\/2020"],"award-info":[{"award-number":["LA\/P\/0045\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT\/MCTES (PIDDAC)","doi-asserted-by":"publisher","award":["UIDB\/00511\/2020"],"award-info":[{"award-number":["UIDB\/00511\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT\/MCTES (PIDDAC)","doi-asserted-by":"publisher","award":["UIDP\/00511\/2020"],"award-info":[{"award-number":["UIDP\/00511\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT\/MCTES (PIDDAC)","doi-asserted-by":"publisher","award":["EXPL\/NAN-MAT\/0209\/2021"],"award-info":[{"award-number":["EXPL\/NAN-MAT\/0209\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT\/MCTES (PIDDAC)","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000054"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000054"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT\/MCTES (PIDDAC)","doi-asserted-by":"publisher","award":["EXPL\/NAN-MAT\/0209\/2021"],"award-info":[{"award-number":["EXPL\/NAN-MAT\/0209\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT\/MCTES (PIDDAC)","doi-asserted-by":"publisher","award":["UI\/BD\/150946\/2021"],"award-info":[{"award-number":["UI\/BD\/150946\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT\/MCTES (PIDDAC)","doi-asserted-by":"publisher","award":["SFRH\/BD\/040932\/2020"],"award-info":[{"award-number":["SFRH\/BD\/040932\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT\/MCTES (PIDDAC)","doi-asserted-by":"publisher","award":["CEEC-IND\/01741\/2021"],"award-info":[{"award-number":["CEEC-IND\/01741\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"Norte Portugal Regional Operational Program (NORTE 2020)","doi-asserted-by":"publisher","award":["LA\/P\/0045\/2020"],"award-info":[{"award-number":["LA\/P\/0045\/2020"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"Norte Portugal Regional Operational Program (NORTE 2020)","doi-asserted-by":"publisher","award":["UIDB\/00511\/2020"],"award-info":[{"award-number":["UIDB\/00511\/2020"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"Norte Portugal Regional Operational Program (NORTE 2020)","doi-asserted-by":"publisher","award":["UIDP\/00511\/2020"],"award-info":[{"award-number":["UIDP\/00511\/2020"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"Norte Portugal Regional Operational Program (NORTE 2020)","doi-asserted-by":"publisher","award":["EXPL\/NAN-MAT\/0209\/2021"],"award-info":[{"award-number":["EXPL\/NAN-MAT\/0209\/2021"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"Norte Portugal Regional Operational Program (NORTE 2020)","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000054"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000054"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"Norte Portugal Regional Operational Program (NORTE 2020)","doi-asserted-by":"publisher","award":["EXPL\/NAN-MAT\/0209\/2021"],"award-info":[{"award-number":["EXPL\/NAN-MAT\/0209\/2021"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"Norte Portugal Regional Operational Program (NORTE 2020)","doi-asserted-by":"publisher","award":["UI\/BD\/150946\/2021"],"award-info":[{"award-number":["UI\/BD\/150946\/2021"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"Norte Portugal Regional Operational Program (NORTE 2020)","doi-asserted-by":"publisher","award":["SFRH\/BD\/040932\/2020"],"award-info":[{"award-number":["SFRH\/BD\/040932\/2020"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"Norte Portugal Regional Operational Program (NORTE 2020)","doi-asserted-by":"publisher","award":["CEEC-IND\/01741\/2021"],"award-info":[{"award-number":["CEEC-IND\/01741\/2021"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["LA\/P\/0045\/2020"],"award-info":[{"award-number":["LA\/P\/0045\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["UIDB\/00511\/2020"],"award-info":[{"award-number":["UIDB\/00511\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["UIDP\/00511\/2020"],"award-info":[{"award-number":["UIDP\/00511\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["EXPL\/NAN-MAT\/0209\/2021"],"award-info":[{"award-number":["EXPL\/NAN-MAT\/0209\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000054"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000054"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["EXPL\/NAN-MAT\/0209\/2021"],"award-info":[{"award-number":["EXPL\/NAN-MAT\/0209\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["UI\/BD\/150946\/2021"],"award-info":[{"award-number":["UI\/BD\/150946\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["SFRH\/BD\/040932\/2020"],"award-info":[{"award-number":["SFRH\/BD\/040932\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["CEEC-IND\/01741\/2021"],"award-info":[{"award-number":["CEEC-IND\/01741\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Scientific Employment Stimulus\u2014Individual Call","doi-asserted-by":"publisher","award":["LA\/P\/0045\/2020"],"award-info":[{"award-number":["LA\/P\/0045\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Scientific Employment Stimulus\u2014Individual Call","doi-asserted-by":"publisher","award":["UIDB\/00511\/2020"],"award-info":[{"award-number":["UIDB\/00511\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Scientific Employment Stimulus\u2014Individual Call","doi-asserted-by":"publisher","award":["UIDP\/00511\/2020"],"award-info":[{"award-number":["UIDP\/00511\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Scientific Employment Stimulus\u2014Individual Call","doi-asserted-by":"publisher","award":["EXPL\/NAN-MAT\/0209\/2021"],"award-info":[{"award-number":["EXPL\/NAN-MAT\/0209\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Scientific Employment Stimulus\u2014Individual Call","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000054"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000054"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Scientific Employment Stimulus\u2014Individual Call","doi-asserted-by":"publisher","award":["EXPL\/NAN-MAT\/0209\/2021"],"award-info":[{"award-number":["EXPL\/NAN-MAT\/0209\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Scientific Employment Stimulus\u2014Individual Call","doi-asserted-by":"publisher","award":["UI\/BD\/150946\/2021"],"award-info":[{"award-number":["UI\/BD\/150946\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Scientific Employment Stimulus\u2014Individual Call","doi-asserted-by":"publisher","award":["SFRH\/BD\/040932\/2020"],"award-info":[{"award-number":["SFRH\/BD\/040932\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Scientific Employment Stimulus\u2014Individual Call","doi-asserted-by":"publisher","award":["CEEC-IND\/01741\/2021"],"award-info":[{"award-number":["CEEC-IND\/01741\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Prize Maratona da Sa\u00fade for Cancer Research","award":["LA\/P\/0045\/2020"],"award-info":[{"award-number":["LA\/P\/0045\/2020"]}]},{"name":"Prize Maratona da Sa\u00fade for Cancer Research","award":["UIDB\/00511\/2020"],"award-info":[{"award-number":["UIDB\/00511\/2020"]}]},{"name":"Prize Maratona da Sa\u00fade for Cancer Research","award":["UIDP\/00511\/2020"],"award-info":[{"award-number":["UIDP\/00511\/2020"]}]},{"name":"Prize Maratona da Sa\u00fade for Cancer Research","award":["EXPL\/NAN-MAT\/0209\/2021"],"award-info":[{"award-number":["EXPL\/NAN-MAT\/0209\/2021"]}]},{"name":"Prize Maratona da Sa\u00fade for Cancer Research","award":["NORTE-01-0145-FEDER-000054"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000054"]}]},{"name":"Prize Maratona da Sa\u00fade for Cancer Research","award":["EXPL\/NAN-MAT\/0209\/2021"],"award-info":[{"award-number":["EXPL\/NAN-MAT\/0209\/2021"]}]},{"name":"Prize Maratona da Sa\u00fade for Cancer Research","award":["UI\/BD\/150946\/2021"],"award-info":[{"award-number":["UI\/BD\/150946\/2021"]}]},{"name":"Prize Maratona da Sa\u00fade for Cancer Research","award":["SFRH\/BD\/040932\/2020"],"award-info":[{"award-number":["SFRH\/BD\/040932\/2020"]}]},{"name":"Prize Maratona da Sa\u00fade for Cancer Research","award":["CEEC-IND\/01741\/2021"],"award-info":[{"award-number":["CEEC-IND\/01741\/2021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Neurodegenerative diseases are caused by the gradual loss of neurons\u2019 function. These neurological illnesses remain incurable, and current medicines only alleviate the symptoms. Given the social and economic burden caused by the rising frequency of neurodegenerative diseases, there is an urgent need for the development of appropriate therapeutics. Natural compounds are gaining popularity as alternatives to synthetic drugs due to their neuroprotective properties and higher biocompatibility. While natural compounds\u2019 therapeutic effects for neurodegenerative disease treatment have been investigated in numerous in vitro and in vivo studies, only few have moved to clinical trials. This article provides the first systematic review of the clinical trials evaluating natural compounds\u2019 safety and efficacy for the treatment of the five most prevalent neurodegenerative disorders: Alzheimer\u2019s disease, Parkinson\u2019s disease, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington\u2019s disease.<\/jats:p>","DOI":"10.3390\/pharmaceutics15010212","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T03:25:58Z","timestamp":1673234758000},"page":"212","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Therapeutic Potential of Natural Compounds in Neurodegenerative Diseases: Insights from Clinical Trials"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6918-8775","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Andrade","sequence":"first","affiliation":[{"name":"LEPABE\u2014Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal"},{"name":"ALiCE\u2014Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9680-8765","authenticated-orcid":false,"given":"D\u00e9bora","family":"Nunes","sequence":"additional","affiliation":[{"name":"LEPABE\u2014Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal"},{"name":"ALiCE\u2014Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal"}]},{"given":"Meghna","family":"Dabur","sequence":"additional","affiliation":[{"name":"LEPABE\u2014Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal"},{"name":"ALiCE\u2014Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2428-7520","authenticated-orcid":false,"given":"Maria J.","family":"Ramalho","sequence":"additional","affiliation":[{"name":"LEPABE\u2014Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal"},{"name":"ALiCE\u2014Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8505-3432","authenticated-orcid":false,"given":"Maria C.","family":"Pereira","sequence":"additional","affiliation":[{"name":"LEPABE\u2014Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal"},{"name":"ALiCE\u2014Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9841-3967","authenticated-orcid":false,"given":"Joana A.","family":"Loureiro","sequence":"additional","affiliation":[{"name":"LEPABE\u2014Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal"},{"name":"ALiCE\u2014Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,7]]},"reference":[{"key":"ref_1","unstructured":"Ramalho, M.J., Andrade, S., Dabur, M., Loureiro, J.A., and Pereira, M.C. (2021). Current vs. Emerging Natural Com-Pounds-Based Treatments for Alzheimer\u2019s Disease. Alzheimer\u2019s Disease and Treatment, MedDocs Publishers."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Andrade, S., Ramalho, M.J., Loureiro, J.A., and Pereira, M.C. (2019). Natural compounds for Alzheimer\u2019s disease therapy: A systematic review of preclinical and clinical studies. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092313"},{"key":"ref_3","first-page":"1","article-title":"Biomarker Detection of Neurological Disorders through Spectroscopy Analysis","volume":"4","author":"Khan","year":"2018","journal-title":"Int. Dent. Med. J. Adv. Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Farooqui, A.A. (2016). Neurochemical Aspects of Neurological Disorders. Trace Amines and Neurological Disorders, Elsevier.","DOI":"10.1016\/B978-0-12-803603-7.00016-1"},{"key":"ref_5","unstructured":"World Health Organization (2018). The Global Dementia Observatory Reference Guide, World Health Organization."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11011-019-00516-y","article-title":"Mechanisms of action of amyloid-beta and its precursor protein in neuronal cell death","volume":"35","author":"Leong","year":"2020","journal-title":"Metab. Brain Dis."},{"key":"ref_7","unstructured":"International, A.s.D. (2022). World Alzheimer Report 2022 Life after Diagnosis: Navigating Treatment, Care and Support, Alzheimer\u2019s Disease International."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1136\/bmj.l6217","article-title":"Cognitive symptoms of Alzheimer\u2019s disease: Clinical management and prevention","volume":"367","author":"Joe","year":"2019","journal-title":"BMJ"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X15666170116143743","article-title":"The Amyloid Cascade Hypothesis in Alzheimer\u2019s Disease: It\u2019s Time to Change Our Mind","volume":"15","author":"Ricciarelli","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jalz.2019.09.075","article-title":"The path forward in Alzheimer\u2019s disease therapeutics: Reevaluating the amyloid cascade hypothesis","volume":"16","author":"Tolar","year":"2019","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"661","DOI":"10.20344\/amp.11978","article-title":"[Parkinson\u2019s Disease: Clinical Review and Update]","volume":"32","author":"Cabreira","year":"2019","journal-title":"Acta Med. Port."},{"key":"ref_12","unstructured":"Stoker, T.B., and Greenland, J.C. (2018). Parkinson\u2019s Disease: Etiology, Neuropathology, and Pathogenesis. Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects, Codon Publications."},{"key":"ref_13","unstructured":"World Health Organization (2022). Parkinson Disease: A Public Health Approach: Technical Brief, World Health Organization."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2217\/nnm.14.27","article-title":"Targeting nanoparticles across the blood\u2013brain barrier with monoclonal antibodies","volume":"9","author":"Loureiro","year":"2014","journal-title":"Nanomedicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2741\/S415","article-title":"Parkinson\u2019s disease: A review","volume":"6","author":"Beitz","year":"2014","journal-title":"Front. Biosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1177\/1352458520968811","article-title":"Atlas of MS 2020: Informing global policy change","volume":"26","author":"Coetzee","year":"2020","journal-title":"Mult. Scler. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler. J."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kennedy, P.G., George, W., and Yu, X. (2022). The Possible Role of Neural Cell Apoptosis in Multiple Sclerosis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23147584"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"877","DOI":"10.30773\/pi.2019.0106","article-title":"Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art","volume":"16","author":"Silveira","year":"2019","journal-title":"Psychiatry Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ctim.2019.02.010","article-title":"The effect of exercise, yoga and physiotherapy on the quality of life of people with multiple sclerosis: Systematic review and meta-analysis","volume":"43","author":"Alphonsus","year":"2019","journal-title":"Complement. Ther. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"117070","DOI":"10.1016\/j.jns.2020.117070","article-title":"Exosomal TAR DNA-binding protein-43 and neurofilaments in plasma of amyotrophic lateral sclerosis patients: A longitudinal follow-up study","volume":"418","author":"Chen","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/WCO.0000000000000730","article-title":"Epidemiology of amyotrophic lateral sclerosis: An update of recent literature","volume":"32","author":"Longinetti","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ncl.2015.07.009","article-title":"Potential Environmental Factors in Amyotrophic Lateral Sclerosis","volume":"33","author":"Oskarsson","year":"2015","journal-title":"Neurol. Clin."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"17085","DOI":"10.1038\/nrdp.2017.85","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e061624","DOI":"10.1136\/bmjopen-2022-061624","article-title":"Effects of respiratory physiotherapy in patients with amyotrophic lateral sclerosis: Protocol for a systematic review of randomised controlled trials","volume":"12","author":"Pondofe","year":"2022","journal-title":"BMJ Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"a007476","DOI":"10.1101\/cshperspect.a007476","article-title":"Huntington\u2019s Disease","volume":"3","author":"Finkbeiner","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/mds.29228","article-title":"Prevalence and Incidence of Huntington\u2019s Disease: An Updated Systematic Review and Meta-Analysis","volume":"37","author":"Medina","year":"2022","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_29","unstructured":"United Nations Department of Economic and Social Affairs (2022). World Population Prospects 2022: Summary of Results, United Nations Department of Economic and Social Affairs."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: From molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1126\/science.1056784","article-title":"Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity","volume":"291","author":"Nucifora","year":"2001","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: Advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Leuci, R., Brunetti, L., Poliseno, V., Laghezza, A., Loiodice, F., Tortorella, P., and Piemontese, L. (2020). Natural compounds for the prevention and treatment of cardiovascular and neurodegenerative diseases. Foods, 10.","DOI":"10.3390\/foods10010029"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Springob, K., and Kutchan, T.M. (2009). Introduction to the different classes of natural products. Plant-derived natural products, Springer.","DOI":"10.1007\/978-0-387-85498-4_1"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1080\/10408398.2019.1653822","article-title":"Phenylpropanoids and its derivatives: Biological activities and its role in food, pharmaceutical and cosmetic industries","volume":"60","author":"Neelam","year":"2020","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_36","first-page":"15","article-title":"Phenylpropanoids as naturally occurring antioxidants: From plant defense to human health","volume":"53","author":"Korkina","year":"2007","journal-title":"Cell. Mol. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12934-020-01367-4","article-title":"Biosynthesis of aromatic polyketides in microorganisms using type II polyketide synthases","volume":"19","author":"Wang","year":"2020","journal-title":"Microb. Cell Factories"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Cox-Georgian, D., Ramadoss, N., Dona, C., and Basu, C. (2019). Therapeutic and Medicinal Uses of Terpenes. Med. Plants, 333\u2013359.","DOI":"10.1007\/978-3-030-31269-5_15"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Pal, A., and Das, S. (2019). Terpenoids in Treatment of Neurodegenerative Disease. Terpenoids Against Human Diseases, CRC Press.","DOI":"10.1201\/9781351026703-5"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archneurol.2012.85","article-title":"Antioxidants for Alzheimer Disease: A Randomized Clinical Trial With Cerebrospinal Fluid Biomarker Measures","volume":"69","author":"Galasko","year":"2012","journal-title":"Arch. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJM199704243361704","article-title":"A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer\u2019s Disease","volume":"336","author":"Sano","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2013.282834","article-title":"Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial","volume":"311","author":"Dysken","year":"2014","journal-title":"JAMA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/WNN.0b013e31826df647","article-title":"Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: A pre-post pilot study","volume":"25","author":"Annweiler","year":"2012","journal-title":"Cogn. Behav. Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jama.300.15.1774","article-title":"High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial","volume":"300","author":"Aisen","year":"2008","journal-title":"JAMA"},{"key":"ref_45","unstructured":"(2022, October 23). ClinicalTrials.gov. Identifier: NCT00580931, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00580931."},{"key":"ref_46","unstructured":"(2022, October 23). Clinicaltrials.gov. Identifier: NCT01594346, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01594346."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.2010.1510","article-title":"Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial","volume":"304","author":"Quinn","year":"2010","journal-title":"JAMA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3233\/JAD-180759","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer\u2019s Disease","volume":"67","author":"Farlow","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","article-title":"A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease","volume":"77","author":"Salloway","year":"2011","journal-title":"Neurology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1212\/WNL.0000000000002035","article-title":"A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease","volume":"85","author":"Turner","year":"2015","journal-title":"Neurology"},{"key":"ref_51","first-page":"609","article-title":"A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer\u2019s disease: A pilot study","volume":"4","author":"Zhu","year":"2018","journal-title":"Alzheimers Dement"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/alzrt146","article-title":"Oral curcumin for Alzheimer\u2019s disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study","volume":"4","author":"Ringman","year":"2012","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/jcp.0b013e318160862c","article-title":"Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease","volume":"28","author":"Baum","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1212\/WNL.0b013e318216eb7b","article-title":"A phase II trial of huperzine A in mild to moderate Alzheimer disease","volume":"76","author":"Rafii","year":"2011","journal-title":"Neurology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer\u2019s disease\u2013A randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch. Med. Sci."},{"key":"ref_56","first-page":"947","article-title":"Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer\u2019s disease: A 6-month, randomized, placebo-controlled, multicenter trial","volume":"9","author":"Wade","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"ref_57","unstructured":"(2022, October 23). ClinicalTrials.gov. Identifier: NCT00951834, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00951834."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1096\/fj.03-0961fje","article-title":"Early vitamin E supplementation in young but not aged mice reduces A\u03b2 levels and amyloid deposition in a transgenic model of Alzheimer\u2019s disease","volume":"18","author":"Sung","year":"2004","journal-title":"FASEB J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/14740338.2018.1524870","article-title":"The efficacy and safety of memantine for the treatment of Alzheimer\u2019s disease","volume":"17","author":"Matsunaga","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Grimm, M.O., Thiel, A., Lauer, A.A., Winkler, J., Lehmann, J., Regner, L., Nelke, C., Janitschke, D., Benoist, C., and Streidenberger, O. (2017). Vitamin D and its analogues decrease amyloid-\u03b2 (A\u03b2) formation and increase A\u03b2-degradation. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122764"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1007\/s12035-017-0839-1","article-title":"Vitamin D improves neurogenesis and cognition in a mouse model of Alzheimer\u2019s disease","volume":"55","author":"Morello","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_62","unstructured":"(2022, October 24). ClinicalTrials.gov. Identifier: NCT01409694, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01409694."},{"key":"ref_63","first-page":"391","article-title":"Omega 3 fatty acids and the brain: Review of studies in depression","volume":"16","author":"Sinclair","year":"2007","journal-title":"Asia Pac. J. Clin. Nutr."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1471-4159.2009.06336.x","article-title":"Mechanism of docosahexaenoic acid-induced inhibition of in vitro A\u03b21\u201342 fibrillation and A\u03b21\u201342-induced toxicity in SH-S5Y5 cells","volume":"111","author":"Hossain","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1523\/JNEUROSCI.4225-04.2005","article-title":"A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model","volume":"25","author":"Lim","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3109\/13880209.2013.804100","article-title":"Marine natural products: Bryostatins in preclinical and clinical studies","volume":"52","author":"Rajchard","year":"2014","journal-title":"Pharm. Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1567205012666141218141904","article-title":"Acute Oral Bryostatin-1 Administration Improves Learning Deficits in the APP\/PS1 Transgenic Mouse Model of Alzheimer\u2019s Disease","volume":"12","author":"Schrott","year":"2015","journal-title":"Curr. Alzheimer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"11141","DOI":"10.1073\/pnas.0403921101","article-title":"Therapeutic effects of PKC activators in Alzheimer\u2019s disease transgenic mice","volume":"101","author":"Etcheberrigaray","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nm1423","article-title":"Cyclohexanehexol inhibitors of A\u03b2 aggregation prevent and reverse Alzheimer phenotype in a mouse model","volume":"12","author":"McLaurin","year":"2006","journal-title":"Nat. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3389\/fnins.2016.00598","article-title":"Resveratrol attenuates formaldehyde induced hyperphosphorylation of tau protein and cytotoxicity in N2a cells","volume":"10","author":"He","year":"2017","journal-title":"Front. Neurosci."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Andrade, S., Loureiro, J.A., Coelho, M.A., and do Carmo Pereira, M. (2015, January 26\u201328). Interaction studies of amyloid beta-peptide with the natural compound resveratrol. In Proceedings of 2015 IEEE 4th Portuguese Meeting on Bioengineering (ENBENG), Porto, Portugal.","DOI":"10.1109\/ENBENG.2015.7088833"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"37377","DOI":"10.1074\/jbc.M508246200","article-title":"Resveratrol promotes clearance of Alzheimer\u2019s disease amyloid-\u03b2 peptides","volume":"280","author":"Marambaud","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1074\/jbc.M404751200","article-title":"Curcumin inhibits formation of amyloid \u03b2 oligomers and fibrils, binds plaques, and reduces amyloid in vivo","volume":"280","author":"Yang","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fphar.2016.00261","article-title":"Curcumin Attenuates Beta-Amyloid-Induced Neuroinflammation via Activation of Peroxisome Proliferator-Activated Receptor-Gamma Function in a Rat Model of Alzheimer\u2019s Disease","volume":"7","author":"Liu","year":"2016","journal-title":"Front. Pharm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/14737175.2016.1175303","article-title":"Huperzine A as a neuroprotective and antiepileptic drug: A review of preclinical research","volume":"16","author":"Damar","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1358\/dot.2006.42.5.973584","article-title":"Tramiprosate","volume":"42","author":"Wright","year":"2006","journal-title":"Drugs Today"},{"key":"ref_77","unstructured":"Krzywkowski, P., Sebastiani, G., Williams, S., Delorme, D., and Greenberg, B. (2007, January 14\u201318). Tramiprosate prevents amyloid beta-induced inhibition of long-term potentiation in rat hippocampal slices. In Proceedings of 8th International Conference AD\/PD, Salzburg, Austria."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","article-title":"Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis","volume":"28","author":"Gervais","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","article-title":"Effect of tramiprosate in patients with mild-to-moderate alzheimer\u2019s disease: Exploratory analyses of the MRI sub-group of the alphase study","volume":"13","author":"Gauthier","year":"2009","journal-title":"JNHA\u2014J. Nutr. Health Aging"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/jpi.12260","article-title":"Melatonin regulates the transcription of \u03b2APP-cleaving secretases mediated through melatonin receptors in human neuroblastoma SH-SY5Y cells","volume":"59","author":"Panmanee","year":"2015","journal-title":"J. Pineal Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/WNR.0000000000000803","article-title":"(-)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer\u2019s disease","volume":"28","author":"Guo","year":"2017","journal-title":"Neuroreport"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3233\/JAD-140981","article-title":"Beneficial effects of dietary EGCG and voluntary exercise on behavior in an Alzheimer\u2019s disease mouse model","volume":"44","author":"Walker","year":"2015","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.febslet.2014.11.026","article-title":"The green tea polyphenol (\u2212)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios","volume":"589","author":"Wobst","year":"2015","journal-title":"FEBS Lett."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1179\/1476830515Y.0000000038","article-title":"Epigallocatechin-3-gallate enhances clearance of phosphorylated tau in primary neurons","volume":"19","author":"Chesser","year":"2016","journal-title":"Nutr. Neurosci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3389\/fneur.2019.00424","article-title":"Nicotine Bitartrate Reduces Falls and Freezing of Gait in Parkinson Disease: A Reanalysis","volume":"10","author":"Lieberman","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1212\/WNL.0000000000004568","article-title":"Caffeine as symptomatic treatment for Parkinson disease (Caf\u00e9-PD): A randomized trial","volume":"89","author":"Postuma","year":"2017","journal-title":"Neurology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1089\/can.2019.0068","article-title":"Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study","volume":"5","author":"Leehey","year":"2020","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000333790","article-title":"Effects of exercise and B vitamins on homocysteine and glutathione in Parkinson\u2019s disease: A randomized trial","volume":"10","author":"Lamberg","year":"2012","journal-title":"Neurodegener Dis"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Wakade, C., Chong, R., Seamon, M., Purohit, S., Giri, B., and Morgan, J.C. (2021). Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson\u2019s Disease: A Single-Center, Randomized, Placebo-Controlled Trial. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121881"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Hiller, A.L., Murchison, C.F., Lobb, B.M., O\u2019Connor, S., O\u2019Connor, M., and Quinn, J.F. (2018). A randomized, controlled pilot study of the effects of vitamin D supplementation on balance in Parkinson\u2019s disease: Does age matter?. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0203637"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","article-title":"A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: No evidence of benefit","volume":"71","author":"Beal","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_92","unstructured":"(2022, October 25). ClinicalTrials.gov. Identifier: NCT01563913, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01563913."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Chan, P., Qin, Z., Zheng, Z., Zhang, L., Fang, X., Sun, F., Gu, Z., Chen, S., Ma, J., and Meng, C. (2009). P2.204 A randomized, double-blind, placebo-controlled, delayed start study to assess safty, tolerability and efflcacy of green tea polyphenols in Parkinson\u2019s disease. Park. Relat. Disord.-Park. Relat Disord, 15.","DOI":"10.1016\/S1353-8020(09)70555-3"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bcp.2009.05.003","article-title":"Multiple roles for nicotine in Parkinson\u2019s disease","volume":"78","author":"Quik","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"ref_95","unstructured":"(2022, October 25). ClinicalTrials.gov. Identifier: NCT03865121, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03865121."},{"key":"ref_96","unstructured":"(2022, October 25). ClinicalTrials.gov. Identifier: NCT02452125, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02452125."},{"key":"ref_97","unstructured":"(2022, October 25). ClinicalTrials.gov. Identifier: NCT00873392, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00873392."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"602697","DOI":"10.3389\/fnins.2020.602697","article-title":"Caffeine and Parkinson\u2019s Disease: Multiple Benefits and Emerging Mechanisms","volume":"14","author":"Ren","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1212\/WNL.0b013e318263570d","article-title":"Caffeine for treatment of Parkinson disease: A randomized controlled trial","volume":"79","author":"Postuma","year":"2012","journal-title":"Neurology"},{"key":"ref_100","unstructured":"(2022, October 26). ClinicalTrials.gov. Identifier: NCT00459420, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00459420."},{"key":"ref_101","unstructured":"(2022, October 26). ClinicalTrials.gov. Identifier: NCT01190735, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01190735."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881114550355","article-title":"Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: An exploratory double-blind trial","volume":"28","author":"Chagas","year":"2014","journal-title":"Journal of Psychopharmacology"},{"key":"ref_103","unstructured":"(2022, October 26). ClinicalTrials.gov. Identifier: NCT03582137, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03582137."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"9426867","DOI":"10.1155\/2019\/9426867","article-title":"Benefits of Vitamins in the Treatment of Parkinson\u2019s Disease","volume":"2019","author":"Zhao","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"107976","DOI":"10.1016\/j.neuropharm.2020.107976","article-title":"Docosahexaenoic acid protects motor function and increases dopamine synthesis in a rat model of Parkinson\u2019s disease via mechanisms associated with increased protein kinase activity in the striatum","volume":"167","author":"Chitre","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.3390\/molecules25173926","article-title":"Neuroprotective Properties of Green Tea in Parkinson\u2019s Disease A","volume":"25","author":"alar","year":"2020","journal-title":"Review. Molecules"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"977521","DOI":"10.3389\/fphar.2022.977521","article-title":"Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson\u2019s disease","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1212\/NXI.0000000000000597","article-title":"Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE)","volume":"6","author":"Camu","year":"2019","journal-title":"Neurol.-Neuroimmunol. Neuroinflamm."},{"key":"ref_109","first-page":"13","article-title":"Effect of Vitamin A Supplementation on Fatigue and Depression in Multiple Sclerosis Patients: A Double-blind Placebo-controlled Clinical Trial","volume":"15","author":"Sama","year":"2016","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"ref_110","first-page":"435","article-title":"Impact of Vitamin A Supplementation on Disease Progression in Patients with Multiple Sclerosis","volume":"18","author":"Bitarafan","year":"2015","journal-title":"Arch. Iran. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1212\/NXI.0000000000000374","article-title":"Lipoic acid in secondary progressive MS: A randomized controlled pilot trial","volume":"4","author":"Spain","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"ref_112","unstructured":"(2022, October 27). ClinicalTrials.gov. Identifier: NCT00010842, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00010842."},{"key":"ref_113","unstructured":"(2022, October 27). ClinicalTrials.gov. Identifier: NCT02133664, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02133664."},{"key":"ref_114","first-page":"709493","article-title":"Efficacy of Fish Oil on Serum of TNF<i>\u03b1<\/i>, IL-1<i>\u03b2<\/i>, and IL-6 Oxidative Stress Markers in Multiple Sclerosis Treated with Interferon Beta-1b","volume":"2013","author":"Ortiz","year":"2013","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_115","first-page":"589","article-title":"Impact of Melatonin on Motor, Cognitive and Neuroimaging Indices in Patients with Multiple Sclerosis","volume":"14","author":"Tina","year":"2015","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"ref_116","unstructured":"(2022, October 27). ClinicalTrials.gov. Identifier: NCT03740295, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03740295?term=egcg&cond=Multiple+Sclerosis&draw=2&rank=4."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"de la Rubia Ort\u00ed, J.E., Platero, J.L., Yang, I.H., Ceron, J.J., Tvarijonaviciute, A., Sabater, P.S., Benlloch, M., Sancho-Cantus, D., and Sancho, S. (2021). Possible Role of Butyrylcholinesterase in Fat Loss and Decreases in Inflammatory Levels in Patients with Multiple Sclerosis after Treatment with Epigallocatechin Gallate and Coconut Oil: A Pilot Study. Nutrients, 13.","DOI":"10.3390\/nu13093230"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Benlloch, M., Cuerda Ballester, M., Drehmer, E., Platero, J.L., Carrera-Juli\u00e1, S., L\u00f3pez-Rodr\u00edguez, M.M., Ceron, J.J., Tvarijonaviciute, A., Navarro, M.\u00c1., and Moreno, M.L. (2020). Possible Reduction of Cardiac Risk after Supplementation with Epigallocatechin Gallate and Increase of Ketone Bodies in the Blood in Patients with Multiple Sclerosis. A Pilot Study. Nutrients, 12.","DOI":"10.3390\/nu12123792"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Platero, J.L., Cuerda-Ballester, M., Sancho-Cantus, D., Benlloch, M., Ceron, J.J., Peres Rubio, C., Garc\u00eda-Pardo, M.P., L\u00f3pez-Rodr\u00edguez, M.M., and de la Rubia Ort\u00ed, J.E. (2021). The Impact of Epigallocatechin Gallate and Coconut Oil Treatment on Cortisol Activity and Depression in Multiple Sclerosis Patients. Life, 11.","DOI":"10.3390\/life11040353"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"103274","DOI":"10.1016\/j.msard.2021.103274","article-title":"ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial","volume":"56","author":"Petracca","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Feige, J., Moser, T., Bieler, L., Schwenker, K., Hauer, L., and Sellner, J. (2020). Vitamin D Supplementation in Multiple Sclerosis: A Critical Analysis of Potentials and Threats. Nutrients, 12.","DOI":"10.3390\/nu12030783"},{"key":"ref_122","unstructured":"(2022, October 28). ClinicalTrials.gov. Identifier: NCT03610139, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03610139."},{"key":"ref_123","unstructured":"(2022, October 28). ClinicalTrials.gov. Identifier: NCT05340985, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05340985."},{"key":"ref_124","unstructured":"(2022, October 28). ClinicalTrials.gov. Identifier: NCT01817166, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01817166."},{"key":"ref_125","unstructured":"(2022, October 28). ClinicalTrials.gov. Identifier: NCT02096133, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02096133."},{"key":"ref_126","unstructured":"(2022, October 28). ClinicalTrials.gov. Identifier: NCT01005095, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01005095."},{"key":"ref_127","unstructured":"(2022, October 28). ClinicalTrials.gov. Identifier: NCT01440062, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01440062."},{"key":"ref_128","unstructured":"(2022, October 28). ClinicalTrials.gov. Identifier: NCT01490502, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01490502."},{"key":"ref_129","unstructured":"(2022, October 28). ClinicalTrials.gov. Identifier: NCT01432704, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01432704."},{"key":"ref_130","unstructured":"(2022, October 28). ClinicalTrials.gov. Identifier: NCT03385356, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03385356."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12031-016-0781-0","article-title":"The Molecular Mechanisms of Vitamin A Deficiency in Multiple Sclerosis","volume":"60","author":"Sedighiyan","year":"2016","journal-title":"J. Mol. Neurosci."},{"key":"ref_132","first-page":"2055217317729688","article-title":"Serum retinol levels are associated with brain volume loss in patients with multiple sclerosis","volume":"3","author":"Yokote","year":"2017","journal-title":"Mult. Scler. J.\u2014Exp. Transl. Clin."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11940-019-0566-1","article-title":"Lipoic Acid and Other Antioxidants as Therapies for Multiple Sclerosis","volume":"21","author":"Waslo","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/cns.13793","article-title":"Role of lipoic acid in multiple sclerosis","volume":"28","author":"Xie","year":"2022","journal-title":"CNS Neurosci. Ther."},{"key":"ref_135","unstructured":"(2022, October 28). ClinicalTrials.gov. Identifier: NCT00676156, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00676156."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1007\/s12035-017-0813-y","article-title":"Lipoic Acid Stimulates cAMP Production in Healthy Control and Secondary Progressive MS Subjects","volume":"55","author":"Fiedler","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/jcph.1605","article-title":"Gastrointestinal Tolerability and Absorption of R- Versus R,S-Lipoic Acid in Progressive Multiple Sclerosis: A Randomized Crossover Trial","volume":"60","author":"Cameron","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"ref_138","unstructured":"(2022, October 28). ClinicalTrials.gov. Identifier: NCT03161028, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03161028."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.19082\/4899","article-title":"Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial","volume":"9","author":"Khalili","year":"2017","journal-title":"Electron. Physician"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1179\/1476830513Y.0000000060","article-title":"Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial","volume":"17","author":"Khalili","year":"2014","journal-title":"Nutr. Neurosci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/1028415X.2019.1659560","article-title":"Effect of omega-3 fatty acids and fish oil supplementation on multiple sclerosis: A systematic review","volume":"24","author":"AlAmmar","year":"2021","journal-title":"Nutr. Neurosci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10072-019-04137-2","article-title":"The role of melatonin in Multiple Sclerosis","volume":"41","author":"Skarlis","year":"2020","journal-title":"Neurol. Sci."},{"key":"ref_143","unstructured":"(2022, October 28). ClinicalTrials.gov. Identifier: NCT03498131, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03498131."},{"key":"ref_144","unstructured":"(2022, October 28). ClinicalTrials.gov. Identifier: NCT03540485, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03540485."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"615790","DOI":"10.3389\/fneur.2021.615790","article-title":"Retinal thickness analysis in progressive multiple sclerosis patients treated with epigallocatechin gallate: Optical coherence tomography results from the SUPREMES study","volume":"12","author":"Klumbies","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"12237","DOI":"10.1002\/jcp.27965","article-title":"Curcumin as a therapeutic candidate for multiple sclerosis: Molecular mechanisms and targets","volume":"234","author":"Ghanaatian","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"100254","DOI":"10.1016\/j.eclinm.2019.100254","article-title":"High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study","volume":"19","author":"Pageot","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"P7.060","DOI":"10.1212\/WNL.84.14_supplement.P7.060","article-title":"Ultra-high dose methylcobalamin (E0302) prolongs survival of ALS: Report of 7 years\u2019 randomised double-blind, phase 3 clinical trial (ClinicalTrials.gov NCT00444613) (P7.060)","volume":"84","author":"Kaji","year":"2015","journal-title":"Neurology"},{"key":"ref_149","unstructured":"(2022, October 31). ClinicalTrials.gov. Identifier: NCT05095571, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05095571."},{"key":"ref_150","unstructured":"(2022, October 31). ClinicalTrials.gov. Identifier: NCT00372879, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00372879."},{"key":"ref_151","unstructured":"(2022, October 31). ClinicalTrials.gov. Identifier: NCT04244630, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04244630."},{"key":"ref_152","unstructured":"(2022, October 31). ClinicalTrials.gov. Identifier: NCT00919555, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00919555."},{"key":"ref_153","unstructured":"(2022, October 31). ClinicalTrials.gov. Identifier: NCT04499963, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04499963."},{"key":"ref_154","unstructured":"(2022, October 31). ClinicalTrials.gov. Identifier: NCT04654689, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04654689."},{"key":"ref_155","unstructured":"(2022, October 31). ClinicalTrials.gov. Identifier: NCT04997954, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04997954."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jns.2015.04.052","article-title":"Neuroprotective effect of ultra-high dose methylcobalamin in wobbler mouse model of amyotrophic lateral sclerosis","volume":"354","author":"Ikeda","year":"2015","journal-title":"J Neurol Sci"},{"key":"ref_157","unstructured":"(2022, October 31). ClinicalTrials.gov. Identifier: NCT03427086, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03427086."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nm1547","article-title":"ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor","volume":"13","author":"Yang","year":"2007","journal-title":"Nat. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/hmg\/ddw073","article-title":"A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy","volume":"25","author":"Bott","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_160","unstructured":"(2022, October 31). ClinicalTrials.gov. Identifier: NCT03944447, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03944447."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/jnc.14639","article-title":"Effects of cannabinoids in Amyotrophic Lateral Sclerosis (ALS) murine models: A systematic review and meta-analysis","volume":"149","author":"Urbi","year":"2019","journal-title":"J. Neurochem."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s13311-013-0253-y","article-title":"Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice","volume":"11","author":"Mancuso","year":"2014","journal-title":"Neurotherapeutics"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","article-title":"A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease","volume":"263","author":"Sagredo","year":"2016","journal-title":"J. Neurol."},{"key":"ref_164","unstructured":"(2022, October 31). ClinicalTrials.gov. Identifier: NCT01357681, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01357681."},{"key":"ref_165","unstructured":"(2022, October 31). ClinicalTrials.gov. Identifier: NCT02336633, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02336633."},{"key":"ref_166","unstructured":"(2022, October 31). ClinicalTrials.gov. Identifier: NCT03034122, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03034122."},{"key":"ref_167","unstructured":"(2022, October 31). ClinicalTrials.gov. Identifier: NCT04478734, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04478734."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"101209","DOI":"10.1016\/j.arr.2020.101209","article-title":"Emerging potential of cannabidiol in reversing proteinopathies","volume":"65","author":"Dash","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1007\/s12035-016-0048-3","article-title":"Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington\u2019s Disease Models","volume":"54","author":"Naia","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1389200217666160709204826","article-title":"Natural Products Combating Neurodegeneration: Parkinson\u2019s Disease","volume":"18","author":"Solayman","year":"2017","journal-title":"Curr Drug Metab"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.intimp.2018.11.036","article-title":"Natural products: Potential therapeutic agents in multiple sclerosis","volume":"67","author":"Yu","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2174\/1389201016666150118132224","article-title":"Natural compounds used as therapies targeting to amyotrophic lateral sclerosis","volume":"16","author":"Nabavi","year":"2015","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1021\/acschemneuro.0c00824","article-title":"Protective Effect of Natural Products against Huntington\u2019s Disease: An Overview of Scientific Evidence and Understanding Their Mechanism of Action","volume":"12","author":"Lum","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13195-019-0529-5","article-title":"The \u201crights\u201d of precision drug development for Alzheimer\u2019s disease","volume":"11","author":"Cummings","year":"2019","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pneurobio.2018.12.006","article-title":"Comprehensive review of mechanisms of pathogenesis involved in Alzheimer\u2019s disease and potential therapeutic strategies","volume":"174","author":"Sharma","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2020.05.041","article-title":"Nanoparticle-hydrogel superstructures for biomedical applications","volume":"324","author":"Jiang","year":"2020","journal-title":"J. Control Release"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11095-020-02865-1","article-title":"RVG29-Functionalized Lipid Nanoparticles for Quercetin Brain Delivery and Alzheimer\u2019s Disease","volume":"37","author":"Pinheiro","year":"2020","journal-title":"Pharm. Res."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/1\/212\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:02:50Z","timestamp":1760119370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/1\/212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,7]]},"references-count":177,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["pharmaceutics15010212"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15010212","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,7]]}}}